Evidence map›Paper›PMID 33516710›Full record

Trial reportJACC. Clinical electrophysiology2021

A Randomized, Double-Blind, Placebo-Controlled Trial of Intravenous Alcohol to Assess Changes in Atrial Electrophysiology.

Gregory M Marcus, Jonathan W Dukes, Eric Vittinghoff, Gregory Nah, Nitish Badhwar, Joshua D Moss, Randall J Lee, Byron K Lee, Zian H Tseng, Tomos E Walters and 12 more

2 registry-linked trialsOpen access · greenAbstract readRandomized Controlled Trial
In one paragraph

Trial report in JACC. Clinical electrophysiology, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to 2 registered trials, which are not on this map. Cited by 24 papers, 2 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
24citing papers in PubMed, 2 pooled it
6.4field-weighted citation impact, top 2% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT01996943 nacompletednot on this map

Investigating the Effects of Ethanol on Atrial Fibrillation Susceptibility and Pathogenesis

TypeinterventionalSponsorUniversity of California, San FranciscoRan2012 to 2020Enrolled100ConditionsAtrial Fibrillation, AlcoholArmsEthanol, Placebo
NCT06754176 narecruitingnot on this mapstarted 2025, after this paper: background citation

Full-Avoidance vs. Permissive/Regulated Drinking & Outcomes On Fibrillation (FULL-PROOF)

TypeinterventionalSponsorUniversity of California, San FranciscoRan2025 to 2029Enrolled100ConditionsAtrial Fibrillation (AF), Atrial Fibrillation (Paroxysmal)ArmsAlcohol Consumption Randomized Instructions
3 · Its place in the literature

Who cites it

24 citing papers in PubMed, 2 syntheses or guidelines pooled it, 51 citations in OpenAlex.

  1. Guideline
  2. Guideline
  3. Review
  4. Review
  5. Article
  6. Review
  7. Review
  8. Article
  9. Alcohol Intake and Cardiovascular Outcomes in Patients With Atrial Fibrillation: RE-LY AF Registry Analysis.Annals of noninvasive electrocardiology : the official journal of the International Society for Holter and Noninvasive Electrocardiology, Inc · 2025
    Article
  10. Lifestyle and risk factor modification in atrial fibrillation: a European Heart Rhythm Association survey.Europace : European pacing, arrhythmias, and cardiac electrophysiology : journal of the working groups on cardiac pacing, arrhythmias, and cardiac cellular electrophysiology of the European Society of Cardiology · 2025
    Article
  11. Review
  12. Impact of lifestyle risk factors on atrial fibrillation: Mechanisms and prevention approaches - A narrative review.International journal of cardiology. Cardiovascular risk and prevention · 2024
    Review
  13. Article
  14. Review
  15. Review
  16. Review
  17. Article
  18. Alcohol and Atrial Fibrillation.Reviews in cardiovascular medicine · 2023
    Review
  19. Premature Atrial Contraction Location and Atrial Fibrillation Inducibility.Circulation. Arrhythmia and electrophysiology · 2023
    Article
  20. Review
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

22 authors at 4 institutions in 1 country.

Gregory M MarcusDivision of Cardiology, University of California-San Francisco, San Francisco, California, USA. Electronic address: greg.marcus@ucsf.edu.
Jonathan W DukesCardiology Associates Medical Group Inc., Ventura, California, USA.
Eric VittinghoffDepartment of Epidemiology and Biostatistics, University of California-San Francisco, San Francisco, California, USA.
Gregory NahDivision of Cardiology, University of California-San Francisco, San Francisco, California, USA.
Nitish BadhwarDivision of Cardiovascular Medicine, Stanford University Medical Center, Stanford, California, USA.
Joshua D MossDivision of Cardiology, University of California-San Francisco, San Francisco, California, USA.
Randall J LeeDivision of Cardiology, University of California-San Francisco, San Francisco, California, USA.
Byron K LeeDivision of Cardiology, University of California-San Francisco, San Francisco, California, USA.
Zian H TsengDivision of Cardiology, University of California-San Francisco, San Francisco, California, USA.
Tomos E WaltersDivision of Cardiology, University of California-San Francisco, San Francisco, California, USA.
Vasanth VedanthamDivision of Cardiology, University of California-San Francisco, San Francisco, California, USA.
Rachel GladstoneDivision of Cardiology, University of California-San Francisco, San Francisco, California, USA.
Shannon FanDivision of Cardiology, University of California-San Francisco, San Francisco, California, USA.
Emily LeeDivision of Cardiology, University of California-San Francisco, San Francisco, California, USA.
Christina FangDivision of Cardiology, University of California-San Francisco, San Francisco, California, USA.
Kelsey OgomoriDivision of Cardiology, University of California-San Francisco, San Francisco, California, USA.
Trisha HueDepartment of Epidemiology and Biostatistics, University of California-San Francisco, San Francisco, California, USA.
Jeffrey E OlginDivision of Cardiology, University of California-San Francisco, San Francisco, California, USA.
Melvin M ScheinmanDivision of Cardiology, University of California-San Francisco, San Francisco, California, USA.
Henry HsiaDivision of Cardiology, University of California-San Francisco, San Francisco, California, USA.
Vijay A RamchandaniNational Institute of Alcohol Abuse and Alcoholism, Bethesda, Maryland, USA.
Edward P GerstenfeldDivision of Cardiology, University of California-San Francisco, San Francisco, California, USA.
University of California, San Francisco · USMedical Research Associates · USNational Institute on Alcohol Abuse and Alcoholism · USStanford Medicine · US

Funding

Alcohol Pharmacokinetics and Pharmacodynamics in HumansZIAAA000466 · NIAAA · NATIONAL INSTITUTE ON ALCOHOL ABUSE AND ALCOHOLISM · PI RAMCHANDANI, VIJAY ARJUN · 2009 to 2025
$31.2M
Mechanistic Relationships Between Ethanol and Human Atrial FibrillationR01AA022222 · NIAAA · UNIVERSITY OF CALIFORNIA, SAN FRANCISCO · PI GREGORY M MARCUS · 2014 to 2026
$4.4M
NIAAA NIH HHS R01 AA022222
6 · The paper itself

Abstract

objectivesThis study sought to identify acute changes in human atrial electrophysiology during alcohol exposure.

backgroundThe mechanism by which a discrete episode of atrial fibrillation (AF) occurs remains unknown. Alcohol appears to increase the risk for AF, providing an opportunity to study electrophysiologic effects that may render the heart prone to arrhythmia.

methodsIn this randomized, double-blinded, placebo-controlled trial, intravenous alcohol titrated to 0.08% blood alcohol concentration was compared with a volume and osmolarity-matched, masked, placebo in patients undergoing AF ablation procedures. Right, left, and pulmonary vein atrial effective refractory periods (AERPs) and conduction times were measured pre- and post-infusion. Isoproterenol infusions and burst atrial pacing were used to assess AF inducibility.

resultsOf 100 participants (50 in each group), placebo recipients were more likely to be diabetic (22% vs. 4%; p = 0.007) and to have undergone a prior AF ablation (36% vs. 22%; p = 0.005). Pulmonary vein AERPs decreased an average of 12 ms (95% confidence interval: 1 to 22 ms; p = 0.026) in the alcohol group, with no change in the placebo group (p = 0.98). Whereas no statistically significant differences in continuously assessed AERPs were observed, the proportion of AERP sites tested that decreased with alcohol (median: 0.5; interquartile range: 0.6 to 0.6) was larger than with placebo (median: 0.4; interquartile range: 0.2 to 0.6; p = 0.0043). No statistically significant differences in conduction times or in the proportion with inducible AF were observed.

conclusionsAcute exposure to alcohol reduces AERP, particularly in the pulmonary veins. These data demonstrate a direct mechanistic link between alcohol, a common lifestyle exposure, and immediate proarrhythmic effects in human atria. (How Alcohol Induces Atrial Tachyarrhythmias Study [HOLIDAY]; NCT01996943).

Indexed as

Blood Alcohol ContentPulmonary VeinsCardiac ElectrophysiologyDouble-Blind MethodHeart AtriaHeart Conduction SystemHumansBlood Alcohol Contentablationalcoholatrial fibrillationelectrophysiologylifestyle

Identifiers

PMID33516710
PMCPMC9578759
OpenAlexW3127387827

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.